Patents by Inventor Bruce E. Maryanoff

Bruce E. Maryanoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrroline kinase inhibitors
    Patent number: 7524858
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: April 28, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Han-Cheng Zhang, Gee-Hong Kuo, Bruce E. Maryanoff, Hong Ye, David O'Neill, Lan Shen, David F. McComsey
  • Substituted pyrroline kinase inhibitors
    Publication number: 20090093634
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
    Type: Application
    Filed: September 22, 2008
    Publication date: April 9, 2009
    Inventors: Han-Cheng Zhang, Bruce E. Maryanoff, Hong Ye
  • Substituted pyrroline kinase inhibitors
    Publication number: 20090093515
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
    Type: Application
    Filed: September 22, 2008
    Publication date: April 9, 2009
    Inventors: Han-Cheng Zhang, Bruce E. Maryanoff, Hong Ye
  • COLLAGEN-RELATED PEPTIDES AND USES THEREOF
    Publication number: 20090068246
    Abstract: The present invention relates to a collagen-related polypeptide (CRP) having hydrophobic amino acid groups at the N- and C-termini capable of non-covalent self-assembly into collagen mimetic triple helices and fibrils thereof and the synthesis, methods of use and compositions thereof.
    Type: Application
    Filed: July 25, 2008
    Publication date: March 12, 2009
    Inventors: William A. Kinney, Mabel Alamino Cejas, Bruce E. Maryanoff, Thomas Matalenas, Chunlin Yang
  • Substituted pyrroline kinase inhibitors
    Patent number: 7488826
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: February 10, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Han-Cheng Zhang, Bruce E. Maryanoff, Hong Ye
  • Novel inhibitors of chymase
    Publication number: 20090036409
    Abstract: The present invention is directed to a compound of formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof, and methods for treating inflammatory and serine protease mediated disorders.
    Type: Application
    Filed: August 20, 2008
    Publication date: February 5, 2009
    Inventors: Michael J. Hawkins, Michael N. Greco, Eugene Powell, Lawrence De Garavilla, Bruce E. Maryanoff
  • Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists
    Publication number: 20080312257
    Abstract: The present invention is directed to novel bicyclic triazolopyrimidine compounds of Formula (I) or a form thereof: wherein X1, X2, R1, R2, R3 and R4 are as defined herein, and their methods of preparation and use as ADP inhibitors.
    Type: Application
    Filed: October 31, 2007
    Publication date: December 18, 2008
    Inventors: Han-Cheng Zhang, Bruce E. Maryanoff, Hong Ye, Cailin Chen
  • Inhibitors of chymase
    Patent number: 7459444
    Abstract: The present invention is directed to a compound of formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof, and methods for treating inflammatory and serine protease mediated disorders.
    Type: Grant
    Filed: January 18, 2005
    Date of Patent: December 2, 2008
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Michael J. Hawkins, Michael N. Greco, Eugene Powell, Lawrence de Garavilla, Bruce E. Maryanoff
  • Substituted indazoly(indoly)maleimide derivatives as kinase inhibitors
    Patent number: 7439363
    Abstract: The present invention is directed to novel indazolyl-substituted pyrroline compounds of Formula (I): R2 is selected from the group consisting of —C1-8alkyl-Z, —C2-8alkenyl-Z and —C2-8alkynyl-Z; wherein the —C1-8alkyl-Z, —C2-8alkenyl-Z and —C2-8alkynyl-Z and Z is a 5 to 6 member aromatic monocyclic heteroaryl ring having from 2 to 4 heteroatoms. These compounds are useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: October 21, 2008
    Assignee: Janssen Parmaceutica N.V.
    Inventors: Han-Cheng Zhang, Bruce E. Maryanoff, Hong Ye
  • Indazole peptidomimetics as thrombin receptor antagonists
    Patent number: 7417030
    Abstract: The invention is directed to novel indazole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indazole peptidomimetics of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.
    Type: Grant
    Filed: March 30, 2006
    Date of Patent: August 26, 2008
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Han-Cheng Zhang, Bruce E. Maryanoff, Anjali Pandey, Robert M. Scarborough
  • Tricyclic indanyls as integrin inhibitors
    Patent number: 7351711
    Abstract: The present invention is directed to substituted indanyl compounds of Formula (I): Useful for treating integrin-mediated disorders such as, but not limited to unstable angina, thromboemboic disorders, osteoporosis, growth and metastasis of malignant tumors, diabetic retinopathy, arthritis, viral disease and surgical adhesions.
    Type: Grant
    Filed: July 28, 2004
    Date of Patent: April 1, 2008
    Assignee: Janssen Pharmaceutical, N.V.
    Inventors: William A. Kinney, Diane K. Luci, Bruce E. Maryanoff
  • Tricyclic benzodiazepines as vasopressin receptor antagonists
    Patent number: 7317005
    Abstract: The invention is directed to tricyclic benzodiazepines useful as vasopressin receptor antagonists for treating conditions involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising tricyclic benzodiazepines of the present invention and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention are also disclosed.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: January 8, 2008
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: William J. Hoekstra, Alexey B. Dyatkin, Bruce E. Maryanoff, Jay M. Matthews
  • Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators
    Patent number: 7312306
    Abstract: The invention is directed to substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators, their use in wound healing and preventing platelet aggregation. Pharmaceutical compositions comprising the substituted heterocyclic acyl-tripeptides of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: December 25, 2007
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: David F. McComsey, Bruce E. Maryanoff, Michael J. Hawkins
  • Pyridine-containing macroheterococylic compounds as kinase inhibitors
    Publication number: 20070213352
    Abstract: This invention is directed to pyridine-containing macroheterocyclic compounds useful as kinase inhibitors, methods for producing such compounds and methods for treating or preventing a kinase mediated disorder.
    Type: Application
    Filed: March 9, 2007
    Publication date: September 13, 2007
    Inventors: Han-Cheng Zhang, Llorente Vicente R. Bonaga, Claudia K. Derian, Bruce E. Maryanoff, Hong Ye
  • Substituted pyrrolines as kinase inhibitors
    Patent number: 7232906
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
    Type: Grant
    Filed: June 4, 2003
    Date of Patent: June 19, 2007
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Han Cheng Zhang, Bruce E. Maryanoff, David F. McComsey, Kimberly White, Hong Ye, Leonard R. Hecker, Bruce Conway, Keith Demarest
  • Indole peptidomimetics as thrombin receptor antagonists
    Patent number: 7183252
    Abstract: The invention is directed to novel indole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indole peptidomimetics of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: February 27, 2007
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Han-Cheng Zhang, William J. Hoekstra, Bruce E. Maryanoff, David F. McComsey
  • Substituted pyrroline kinase inhibitors
    Patent number: 7125878
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder.
    Type: Grant
    Filed: May 6, 2003
    Date of Patent: October 24, 2006
    Assignee: Janssen Pharmaceutica
    Inventors: Han-Cheng Zhang, Gee-Hong Kuo, Bruce E. Maryanoff, Hong Ye, David O'Neill, Lan Shen, Keith Demarest, Bruce R. Conway, David F. McComsey
  • Indazole peptidomimetics as thrombin receptor antagonists
    Patent number: 7049297
    Abstract: The invention is directed to novel indazole peptidomimetic compounds which are useful as thrombin receptor antagonists for the treatment of diseases associated with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, Angiogenesis related disorders, cancer, and neurodegenerative disorders. Pharmaceutical compositions comprising the substituted indazole peptidomimetics of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: May 23, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Han-Cheng Zhang, Bruce E. Maryanoff, Anjali Pandey, Robert M. Scarborough
  • Substituted pyrrolines as kinase inhibitors
    Patent number: 6987110
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
    Type: Grant
    Filed: June 4, 2003
    Date of Patent: January 17, 2006
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Han-Cheng Zhang, Bruce E. Maryanoff, Hong Ye, Bruce R. Conway, Keith Demarest
  • Aza-bridged-bicyclic amino acid derivatives as ?4 integrin antagonists
    Patent number: 6960597
    Abstract: The invention is directed to aza-bridged-bicyclic compounds having Formula (I): and pharmaceutically acceptable salts thereof. The compounds are useful (?4 integrin receptor antagonists and, in particular, ?4?1 and ?4?7 integrin receptor antagonists. The invention is further directed to methods for use of the instant compounds for treating integrin mediated disorders including, but not limited to, inflammatory disorders, autoimmune disorders and cell-proliferative disorders, methods for preparing the compounds and methods for preparing the intermediates, derivatives and pharmaceutical compositions thereof.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: November 1, 2005
    Assignee: Orth-McNeil Pharmaceutical, Inc.
    Inventors: Alexey B. Dyatkin, Bruce E. Maryanoff, William J. Hoekstra, Wei He, William A. Kinney